We previously demonstrated that detectable BKV replication in donor urine pretransplant was significantly associated with post-transplant recipient BKV viremia. In this 4-year prospective study, we assessed whether recipient BKV replication pretransplant was associated with post-transplant viremia/BKV nephropathy. We studied 220 primary adult and pediatric organ transplant recipients for 490 person-years and 2100 clinical visits. BKV viruria was detectable in 28 (16%), 26 adults and two children; and viremia in none pretransplant. Post-transplant viruria occurred in all recipients with pretransplant BKV viruria, significantly more than in recipients without pretransplant viruria on univariate (P<.005) and multivariate analysis including type of organ trans- 
| INTRODUCTION
The BKV, a human renotropic polyomavirus, was discovered in 1971 1 and since then has been identified as a significant cause of renal allograft dysfunction and loss with the first documented case of BKV nephropathy being published in 1995. 2 Infections with BKV are highly prevalent, and after primary infection, which occurs most commonly in childhood, the viruses persist in renal tubular and uroepithelial cells that serve as reservoirs for reactivation. 3 BKV nephropathy is more common in kidney transplant recipients but can also occur in other immunocompromised transplant recipients [4] [5] [6] [7] and BKV infection even without overt nephropathy has been shown to be associated with renal impairment in kidney, liver, 8 lung, 9 and heart 10 transplant recipients.
We previously showed that donor BKV viruria was associated with increased recipient BKV viremia post-transplant. 11 The role of pretransplant recipient BKV replication on subsequent post-transplant BKV infection is less defined. While pretransplant BK viral replication has been postulated to be a risk factor for post-transplant infection, 12 other studies negate this. [13] [14] [15] We conducted a 4-year prospective study of recipient viral replication in the urine, oral wash, and blood before and after pediatric and adult transplant to study the incidence and role of pretransplant recipient BKV replication on post-transplant recipient BKV outcomes.
Abbreviations: BKV, BK polyomavirus; EDTA, ethylenediamine tetraacetic acid; EIAs, enzyme immunoassays.
| PATIENTS AND METHODS

| Study design
All subjects receiving an organ transplant at the University of Minnesota were consecutively enrolled just prior to transplant and followed for as long as 4 years. Donors and recipients were studied 
| Quantitative viral DNA assays
Viral DNA was extracted from the samples using the The reverse primer was 5′-CTG GGT TTA GGA AGC ATT CTA-3′.
| Data gathering, data coordination, and statistics
The following data were evaluated:
1. Recipient serial measurements of BKV viral loads were treated as categorical variables. A positive viral load was defined as BKV, ≥500 copies/mL of sample. subjects with and without recipients shedding BK virus pretransplant using log-rank analysis. As 48 recipients did not have pretransplant urinary specimens due to anuric/oliguric renal failure, the analysis was repeated in the remaining 172 recipients. Statistical significance was set at a P value <.05, two sided. All statistical analyses were performed using STATA 11.0 software (STATA Corporation, College Station, TX, USA).
| RESULTS
In this 4-year prospective study, we studied 220 primary organ transplant recipients for 490 person-years. We conducted 2100 clinical visits (2-20 visits/recipient) and collected and tested 9081 samples of blood, urine, and oral washes for the quantitative measurement of BKV in primary solid organ transplant recipients and their donors beginning 1-7 days before the transplant ( Table 1 ).
The majority of recipients included were kidney (51%) and liver (31%) recipients. The mean age of recipients was 46.6 years; 28
were pediatric recipients; 37% were female; 85% were Caucasian;
and 57% were deceased donor recipients. All recipients were noted to receive thymoglobulin induction and maintenance immunosuppression varied as noted in Table 2 . Donors were mostly Caucasian and female.
| Pretransplant recipient BKV shedding
There was no BK viremia in any recipients prior to transplant. BK virus was also not detectable in the oral specimens of any recipients prior to transplant. BK virus was detectable in the urine of 28 (16%) recipients prior to transplant (including two pediatric recipients), but urinary samples were unavailable in 48 recipients. Recipients with and without BK viruria were not significantly different except they were more often kidney recipients ( Table 2) . Prevalence of BK viruria in recipients prior to transplant was not significantly different from prevalence of BK viruria in healthy donors (P=.1). Urinary BKV titers prior to transplant in recipients ranged from 900 to 1 514 900 copies/mL (mean 119 032).
| Impact of pretransplant BKV viruria on posttransplant BKV infection/disease
All recipients with pretransplant BKV viruria had post-transplant viruria, significantly more than observed in recipients that did not have viruria prior to transplant (P<.005). Both the pediatric recipients with pretransplant BKV viruria had post-transplant viruria. Time to viruria was also significantly shorter in recipients shedding virus in the urine prior to transplant (P .01; Figure 1 
5).
In fact, only 4 of the 31 recipients to develop post-transplant viremia had pretransplant BKV viruria. One of the two pediatric recipients with pretransplant viruria did have post-transplant BK viremia with BKV PCR 1500-6000 copies/mL but no evidence of BKV nephropathy. The patient did however develop hemorrhagic cystitis, which resolved with immunereduction. When recipients that did not have pretransplant urinary specimens were excluded, the results remained unchanged.
The peak serum BKV PCR post-transplant was not significantly different in recipients with (mean±SD 1200±587 copies/mL) and without (mean±SD 13 780±9104 copies/mL) viruria pretransplant (P=.6). The peak urinary BK PCR post-transplant was not significantly different in recipients with (mean±SD 1445 089±1081 444 copies/mL) and without viruria (mean±SD 855 480±525 338) pretransplant (P=.6).
None of the included cases developed BK nephropathy.
| DISCUSSION
In the largest prospective study of its kind, we demonstrated that pretransplant BKV viruria was NOT associated with an increased incidence of post-transplant BKV viremia or BKV nephropathy. BKVrelated complications are of no less clinical relevance to children, and yet, ours is the first study of its kind to include pediatric recipients.
We have previously demonstrated that BKV viremia after transplant is likely of donor origin and is impacted by donor viral replication in the urine prior to transplant. 11 This study was carried out to assess whether active recipient BKV viruria prior to transplant could also play a role in BKV infection and disease development following immunosuppression and organ transplantation. Pretransplant kidney recipient BKV viruria was independently and significantly associated with posttransplant recipient BKV viruria, but not viremia or BKV nephropathy.
Time to viruria was also significantly shorter after transplant in recipients with BK viruria prior to the transplant. We acknowledge that our study does not allow identification of the source of post-transplant BKV in recipients-native kidneys vs donor kidney, particularly, as the number of recipients that had native nephrectomies at or pretransplant was small. As only 32 (14.5%) patients had less than 1 year post-transplant follow-up, and loss to follow-up was patient death/ graft loss in the majority, we believe it is unlikely that a differential biologic effect in the frequency of progression to BKV nephropathy was missed given that BKV nephropathy is largely recognized as an early event occurring within the first year after transplantation. 16, 17 BKV viruria in the absence of BKV viremia is not usually associated with an increased risk for BKV disease, 18 although in patients with BKV nephropathy, it is often preceded by viruria and then viremia. 17 In our patients, viruria did not predict viremia or nephropathy. We conclude that despite the association of recipient BK viruria pre-and posttransplant, the urinary BKV likely represents asymptomatic shedding of no clinical significance. While we were unable to find an association between pretransplant viruria and post-transplant viremia, it should be acknowledged that BKV viruria is a precursor to BKV viremia, which is a known precursor to BKV nephropathy. Our findings concur with a small 34 recipient study carried out in Sao Paolo, which demonstrated that pretransplant BKV viruria had no impact on post-transplant BKV viremia. The Brazilian study only included adult kidney recipients and excluded recipients with death or graft loss. In their study, all recipients developed BKV viruria post-transplant and the prevalence of pre-and post-transplant BKV viruria was higher than at our center or in other reports. 14 This could reflect geographic differences in BKV strains, an observed phenomenon with this virus. [19] [20] [21] [22] [23] Our findings are also supported by a small 32 recipient study carried out in North India. 13 Contrary to our findings, in 2008, a study demonstrated an increased risk of post-transplant BKV infection with reactivation of latent BKV; however, the viruria testing in this study was carried out by detecting decoy cells, 24 and therefore, their results cannot be compared to the PCR technique utilized in our study. In addition, none of these previous studies included children and the demographics were not comparable to the North American cohort.
Of the 28 children included in this study, only two (7%) had viruria prior to transplant, which is non-significantly less than observed in the 26 (13.5%) adult transplant recipients. This is in keeping with the known high BKV antibody prevalence in adult kidney donors. 25, 26 Of the two children with viruria prior to transplant, one While the lack of BKV antibody data in our study is unfortunate, BKV antibody testing is not routinely carried out at most centers including ours. Another limitation is the lack of uniform immunosuppression; however, this allows for better generalizability of the conclusions of this article. BKV typing to conclusively prove that the post-transplant BKV was recipient vs donor origin was not done.
Limitations include the small size of the pediatric cohort as well as the absence of the calculation of sample size prior to the start of the study.
In conclusion, BKV viruria did occur in adult and pediatric recipients awaiting organ transplantation at a similar rate as healthy donors, but BKV viremia was not confirmed in any recipients awaiting organ transplant. Detectable BKV viral replication, at or before transplant, did not predict post-transplant viremia or BKV nephropathy in kidney or other organ recipients.
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